Akito Nakamura

Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response

Akito Nakamura, Tadahiro Nambu, Shunsuke Ebara et al. · Proceedings of the National Academy of Sciences · 2018 · 170 citations · Full text

Medicine, Oncology, Pharmacology +16

Antitumor Activity of the Selective Pan-RAF Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma

Akito Nakamura, Takeo Arita, Shuntarou Tsuchiya et al. · Cancer Research · 2013 · 126 citations

Medicine, Oncology, Pharmacology +17

Discovery of a Selective Kinase Inhibitor (TAK-632) Targeting Pan-RAF Inhibition: Design, Synthesis, and Biological Evaluation of <i>C</i>-7-Substituted 1,3-Benzothiazole Derivatives

Masanori Okaniwa, Masaaki Hirose, Takeo Arita et al. · Journal of Medicinal Chemistry · 2013 · 112 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation

Akito Nakamura, Stephen Grossman, Keli Song et al. · Blood · 2022 · 71 citations · Full text

Life Sciences, Immunology, Oncology +17

CDK8/19 inhibition induces premature G1/S transition and ATR-dependent cell death in prostate cancer cells

Akito Nakamura, Daisuke Nakata, Yuichi Kakoi et al. · Oncotarget · 2018 · 49 citations · Full text

Life Sciences, Cell Biology, Oncology +17